摘要
目的 :研究拓扑替康 (topotecan)与顺铂联合化疗治疗晚期复发性上皮性卵巢癌的疗效和毒性反应。方法 :我们于 2 0 0 0年 10月至 2 0 0 1年 6月联合应用拓扑替康 1.0mg/ (m2 ·d) ,第 1— 5天与顺铂 2 0mg/ (m2 ·d) ,第1— 3天 ,共治疗 30例晚期复发性卵巢癌。平均用药 2 .4个疗程。结果 :总有效率为 33.3% (10 / 30 ) ,其中CR 4例 ,PR 6例 ;疗效稳定为 36 .7% (11/ 30 ) ;进展为 30 .0 % (9/ 30 ) ,其中 3例于随访中死亡。至随访截止 ,中位无进展期 5月 ,中位生存期 6 .5月。毒性反应以骨髓抑制为主 ,Ⅲ—Ⅳ度白细胞下降为 5 6 .7% (17/ 30 ) ,以中性粒细胞下降为主 ;Ⅲ—Ⅳ度血小板下降为 30 .0 % (9/ 30 ) ;Ⅲ—Ⅳ度血红蛋白下降为 30 .0 % (9/ 30 )。无严重并发症发生。恶心、呕吐发生率为 86 .7% ,脱发占 83.3%。结论 :本方案抗肿瘤效应肯定 ,但血液学毒副反应较大 。
Purpose:To study the therapeutic effect and toxic reaction of salvage chemotherapy with topotecan and cisplatin in patients with advanced recurrent epithelial ovarian cancer.Methods:Thirty patients entered this multicenter pilot study from October 2000 to June 2001. They received cisplatin at 20 mg/(m 2·d) from day 1 to day 3 and topotecan at 1.0 mg/(m 2·d) from day 1 to day 5 every 18 days. The average cycle was 2.4. Results:The overall response rate was 33.3 % (10/30), among which complete response was seen in 4 cases and partial response in 6 cases. 36.7 % (11/30) had stable disease and 30.0 % (9/30) had progression, 3 of them died during follow up. Until the end of the study, the median progression free interval and survival were 5 months and 6.5 months. The major toxic reaction was myelosuppression with 56.7 % of grade Ⅲ and Ⅳ neutropenia, 30.0 % (9/30) of grade Ⅲ and Ⅳ thrombocytopenia and 30.0 % (9/30) of grade Ⅲ and Ⅳ anemia. No severe complication occurred. Nausea/vomiting and alopecia occureed in 86.7 % and 83.3 % of the cases.Conclusions:This combination regimen has moderate anti tumor activity, but the hematological toxicity is great. It can be selectively used in the patients with advanced recurrent epithelial ovarian cancer as a second line chemotherapy.
出处
《中国癌症杂志》
CAS
CSCD
2001年第5期447-450,共4页
China Oncology
